|Day Low/High||1.71 / 1.76|
|52 Wk Low/High||1.60 / 4.40|
Company provides 2017 highlights and 2018 development program guidance
Specific therapeutic use claim in oral mucositis adds to existing composition of matter claims
2017 Non-Dilutive Funding Exceeds $8.6 Million
2017 Non-Dilutive Funding Exceeds $8M
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.